Una inyección de virus detiene el crecimiento de tumores pancreáticos en un ensayo

29 de mayo de 2026

Reportado por IA

Un virus modificado genéticamente ha detenido el crecimiento de tumores pancreáticos en tres pacientes durante un ensayo clínico inicial en Estados Unidos. Los resultados provienen de un estudio de seguridad dirigido por investigadores de la Universidad de Minnesota.

El primer paciente recibió el tratamiento hace un año tras ser diagnosticado con un tumor de 7 centímetros confinado al páncreas. Los otros dos pacientes fueron tratados posteriormente y los tres permanecen vivos con la enfermedad estable, según Masato Yamamoto, quien dirigió el desarrollo de la terapia. En esta fase inicial se utilizó solo una décima parte de la dosis prevista y, aun así, los tumores no se han extendido ni aumentado de tamaño desde la inyección.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

5 de junio de 2026 Reportado por IA Imagen generada por IA Verificado por hechos

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Engineered phages redirect vaccine immunity to eradicate tumors in mice

Researchers have used genetically modified phages to harness pre-existing vaccine immunity and destroy cancer cells in mice. The approach eradicated tumors in 44 percent of treated animals with no recurrence after a year.

Sugar-coated nanoparticles boost glioblastoma survival in mice

17 de julio de 2026 Reportado por IA

Researchers at Oregon State University have developed an experimental treatment that uses sugar-coated nanoparticles to deliver genetic material across the blood-brain barrier in a mouse model of glioblastoma. The approach restored a tumor-suppressing protein and increased median survival by 50 percent while shrinking tumors without measurable organ toxicity.

Health

Experimental mRNA vaccine shows protection against multiple ebola viruses

Health

FDA-approved drug shows promise against rare liver cancer

Health

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

McGill researchers use reversible drug approach to boost natural killer cells against hard-to-treat cancers

Researchers at McGill University report a drug-based method to temporarily enhance natural killer (NK) cells—an immune cell type—by inhibiting two proteins, improving the cells’ ability to attack several aggressive cancers in preclinical experiments.

USC scientists create renewable supply of cancer-fighting cells

29 de junio de 2026 Reportado por IA

Researchers at USC Stem Cell have developed a method to produce large numbers of immune cell precursors that can be engineered to target cancer. The approach, published in the journal Cell, uses granulocyte-monocyte progenitors that self-renew in the laboratory.

Gene-editing drug slashes bad cholesterol 62 percent in trial

An experimental therapy called VERVE-102 lowered LDL cholesterol by up to 62 percent after a single dose in an early safety study. The results come from a Phase I trial involving 35 patients with high cholesterol or early cardiovascular disease. Data were published this week in the New England Journal of Medicine.

21 de julio de 2026 20:27